IP Library Granted Patent US 11,129,815
Granted Patent B2
US 11,129,815 · App. 16/657,368 · Granted Sep 28, 2021

Solid dispersions comprising tacrolimus

Inventor: Per Holm (Vanlose, DK)
Assignee: VELOXIS PHARMACEUTICALS INC.
A61K31/436A61K9/0053A61K9/10A61K9/1617A61K9/1623A61K9/1641A61K9/1652A61K9/2013A61K9/2018A61K9/2027A61K9/2031A61K9/2054A61K9/2077A61K9/2846A61K31/00A61K31/439A61K31/4745A61K9/1611A61K9/2009A61K9/2095A61K9/2893Y10S514/885
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,129,815
App. No.
16/657,368
Granted
Sep 28, 2021
Kind
B2
Abstract

A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.

Claims (14)

1. A method for the preparation of a solid pharmaceutical composition comprising an active ingredient selected from tacrolimus dispersed or dissolved in a hydrophilic or water-miscible vehicle, wherein the melting point of the vehicle is at least 20° C. and the active ingredient is present therein in a concentration of between about 0.01 w/w % and about 15 w/w %, wherein the method comprises:

(a) dispersing and/or dissolving the active ingredient in the hydrophilic or water- miscible vehicle to form a mixture, and

(b) spraying the mixture onto a solid carrier to obtain the solid pharmaceutical composition.

2. The method according to claim 1 , wherein the active ingredient is partly dissolved in the vehicle to form a mixture of solid dispersion and solid solution at ambient temperature.

3. The method according to claim 1 , wherein the active ingredient is fully dissolved in the vehicle to form a solid solution at ambient temperature.

4. The method according to claim 1 , wherein the hydrophilic or water-miscible vehicle has a melting point of at least 30° C.

5. The method according to claim 1 , wherein the concentration of the active ingredient in the hydrophilic or water-miscible vehicle is at the most 10 w/w %.

6. The method according to claim 1 , wherein the concentration of the active ingredient in the hydrophilic or water-miscible vehicle is at least about 0.05 w/w %.

7. The method according to claim 1 , wherein the hydrophilic or water-miscible vehicle is selected from the group consisting of polyethylene glycols, polyoxyethylene oxides, poloxamers, polyoxyethylene stearates, poly-epsilon caprolactone, polyglycolized glycerides, and mixtures thereof.

8. The method according to claim 1 , wherein the hydrophilic or water-miscible vehicle is selected from the group consisting of polyvinylpyrrolidones, polyvinyl-polyvinylacetate copolymers (PVP-PVA), polyvinyl alcohol (PVA), polymethacrylic polymers, cellulose derivatives, pectins, cyclodextrins, galactomannans, alginates, carragenates, xanthan gums and mixtures thereof.

9. The method according to claim 1 , wherein the vehicle comprises polyethylene glycol (PEG).

10. The method according to claim 9 , wherein the polyethylene glycol has an average molecular weight of at least 1500.

11. The method according to claim 1 , wherein the tacrolimus is dispersed or dissolved in a mixture comprising two or more hydrophilic or water-miscible vehicles.

12. The method according to claim 8 , wherein the cellulose derivatives are selected from hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), methylcellulose, sodium carboxymethylcellulose, hydroxyethyl cellulose, and mixtures thereof.

Assignments (3)
CHANGE OF ADDRESS Recorded Jun 7, 2024
From: VELOXIS PHARMACEUTICALS INC.
To: VELOXIS PHARMACEUTICALS INC.
Reel/Frame 067666/0352 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2021
From: VELOXIS PHARMACEUTICALS A/S
To: VELOXIS PHARMACEUTICALS INC.
Reel/Frame 055815/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2021
From: VELOXIS PHARMACEUTICALS A/S,
To: VELOXIS PHARMACEUTICALS INC.
Reel/Frame 055613/0695 →
Priority Claims (5)
DK PA 2003 01232 · Aug 29, 2003 · national
DK PA 2003 01837 · Dec 11, 2003 · national
DK PA 2004 00079 · Jan 21, 2004 · national
DK PA 2004 00463 · Mar 23, 2004 · national
DK PA 2004 00467 · Mar 23, 2004 · national
Continuity (7)
Continuation 15676727 · Aug 14, 2017
Continuation 14934908 · Nov 6, 2015
Continuation 13721792 · Dec 20, 2012
Continuation 13178280 · Jul 7, 2011
Continuation 10569863
Provisional Application 60529793 · Dec 15, 2003
Related Publication 20200289478A1 · Sep 17, 2020